Abstracts Archive - Page 2548 of 2607 - ACR Meeting Abstracts

Abstract Number: 851 • 2012 ACR/ARHP Annual Meeting
An Evidence-Based Screening Algorithm for Pulmonary Arterial Hypertension in Systemic Sclerosis
James R. Seibold¹, Christopher P. Denton², Ekkehard Grünig³, Diana Bonderman⁴, Oliver Distler⁵, Dinesh Khanna⁶, Ulf Müller-Ladner⁷, Janet E. Pope⁸, Madelon C. Vonk⁹, Martin Doelberg¹⁰, Harbajan Chadha-Boreham¹⁰, Harald Heinzl⁴, Daniel M. Rosenberg¹⁰, Vallerie McLaughlin¹¹ and John G. Coghlan¹², ¹Scleroderma Research Consultants LLC, Avon, CT, ²Department of Rheumatology, Royal Free Hospital, London, United Kingdom, ³University Hospital, Heidelberg, Germany, ⁴Medical University of Vienna, Vienna, Austria, ⁵Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁶Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁷Abt. f. Rheumatologie u. klinische Immunologie, Osteologie, Physikalische Therapie, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, ⁸Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁹Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁰Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, ¹¹Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, ¹²Royal Free Hospital, London, United Kingdom
Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality and late-stage morbidity in systemic sclerosis (SSc). Current PAH screening recommendations are consensus-based and…
Abstract Number: 852 • 2012 ACR/ARHP Annual Meeting
C-Reactive Protein Predicts Long-Term Progression of Interstitial Lung Disease and Survival in Patients with Early Systemic Sclerosis
Xiaochun Liu¹, Maureen D. Mayes¹, John D. Reveille², Emilio B. Gonzalez³, Brock E. Harper⁴, Hilda T. Draeger⁵ and Shervin Assassi⁶, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX, ³Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴Int Med/Rheumatology, University of Texas Medical Branch, Galveston, TX, ⁵Med/Clinical/Immunology, Univ of TX Health Sci Ctr, San Antonio, TX, ⁶Rheumatology, Univ of Texas Health Science Houston, Houston, TX
ABSTRACT:Background/Purpose: The currently available clinical markers are not reliable predictors of long-term progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). In…
Abstract Number: 813 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials
Robert Terkeltaub¹, Robert R. Evans², Steven P. Weinstein³, Richard Wu⁴ and H. Ralph Schumacher⁵, ¹Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ²Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Gout flare (GF) prophylaxis in patients (pts) with chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR]
Abstract Number: 814 • 2012 ACR/ARHP Annual Meeting
Familial Aggregation and Heritability of Gout in Taiwan: A Nationwide Population Study
Chang-Fu Kuo¹, Matthew J. Grainge², Lai-Chu See³, Kuang-Hui Yu⁴, Shue-Fen Luo⁴, Ana M. Valdes⁵, Weiya Zhang¹ and Michael Doherty⁶, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Epidemiology and Public Health, School of Community Health Sciences,, University of Nottingham, Nottingham, United Kingdom, ³Department of Public Health, College of Medicine, Chang Gung University, Chang Gung University, Taoyuan, Taiwan, ⁴Division of Rheumatology, Immunology and Allergy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁵Dept of Twin Research and Genetic Epidemiology, St. Thomas' Hospital, King's College London, London, United Kingdom, ⁶Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: Gout has long been recognised to cluster within families. However, formal evidence for familial aggregation is scant and discordant and the magnitude of any…
Abstract Number: 815 • 2012 ACR/ARHP Annual Meeting
Exploratory Analysis of Radiographic Change in Patients Treated with Intensive Urate-Lowering Therapy
Nicola Dalbeth¹, Anthony Doyle², Fiona M. McQueen³, John S. Sundy⁴ and Herbert S. B. Baraf⁵, ¹Medicine, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ⁴Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, ⁵Arthritis & Rheumatism Associates, Wheaton, MD
Background/Purpose: In patients with gout, tophi are strongly associated with radiographic damage. Effective urate-lowering therapy (ULT) reduces tophus size. However, no studies to date have…
Abstract Number: 816 • 2012 ACR/ARHP Annual Meeting
Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout
Eswar Krishnan, Medicine, Standford University, Palo Alto, CA
Background/Purpose: The kidney is the major organ of urate excretion in humans. Yet, there are few studies that assess whether reduced glomerular filtration and/or kidney…
Abstract Number: 817 • 2012 ACR/ARHP Annual Meeting
Feasibility of Using a Pharnacist-Based Gout Management Clinic to Improve Serum Uric Acid in Gout Patients an a Large Prepaid Health Plan
Robert D. Goldfien¹, Michele S. Ng², Goldie M. Yip², Alice Hwe², Alice Pressman³ and Andy L. Avins³, ¹Kaiser Permanente, Richmond, CA, ²Pharmacy, Kaiser Permanente, Oakland, CA, ³Division of Research, Kaiser Permanente, Oakland, CA
Background/Purpose: Effective treatment for recurrent gout has been hampered by a number of problems including outdated treatment approaches, a failure to treat to target, and…
Abstract Number: 818 • 2012 ACR/ARHP Annual Meeting
Levotofisopam Has Uricosuric Activity and Reduces Serum Urate Levels in Patients with Gout
Robert J. Noveck¹, Zongyao Wang¹, Ann Forsthoefel¹, Kristina Sigmon², Pauliana C. Hall³, John C. Keogh⁴ and John S. Sundy², ¹Duke Clinical Research Unit, Duke University Medical Center, Durham, NC, ²Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, ³PCH Integrated Regulatory Services, Inc., Laguna Niguel, CA, ⁴Keogh Medical Writing, Philadelphia, PA
Background/Purpose: The investigational new drug levotofisopam is the S-enantiomer of racemic tofisopam, a 2,3-benzodiazepine derivative approved in over 20 countries outside the US for treatment…
Abstract Number: 819 • 2012 ACR/ARHP Annual Meeting
Trajectories of Change in Physical Function: Effects On Fractures and Mortality
Kamil E. Barbour¹, Li-Yung Lui², Deborah E. Barnes³, Kristine E. Ensrud⁴, Anne B. Newman⁵, Kristine Yaffe³, Steven R. Cummings⁶ and Jane A. Cauley⁵, ¹Centers for Disease Control and Prevention, Atlanta, GA, ²California Pacific Medical Center, San Francisco, CA, San Francisco, CA, ³University of California San Francisco, San Francisco, CA, San Francisco, CA, ⁴University of Minnesota and Minneapolis VAHS, Minneapolis, MN, Minneapolis, MN, ⁵Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, ⁶San Francisco Coordinating Center, CPMC Research Institute, San Francisco, CA
Background/Purpose: Prior studies have identified poor physical function as a risk factor for fractures and mortality. However, these studies did not consider change in physical…
Abstract Number: 820 • 2012 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Incident Fractures Are Associated with an Increased Risk of Cardiovascular Events
Orla Ni Mhuircheartaigh¹, Cynthia S. Crowson², Sherine E. Gabriel³, Veronique L. Roger⁴, L. Joseph Melton III⁵ and Shreyasee Amin⁶, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research and Cardiology, Mayo Clinic, Rochester, MN, ⁵Department of Hlth Sciences, Mayo Clinic, Rochester, MN, ⁶Health Sciences Research and Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatoid Arthritis (RA) is associated with an increased risk for both fracture (fx) and cardiovascular disease (CVD) and there is increasing evidence establishing a…
Abstract Number: 821 • 2012 ACR/ARHP Annual Meeting
Association of Serum Uric Acid and Incident Fractures in Elderly Men
Nancy E. Lane¹, Neeta Parimi², Barton Wise³, Peggy Cawthon⁴, Eric Orwoll⁵ and MrOS Investigators Group⁶, ¹Internal Medicine, Center for Musculoskeletal Health, UC Davis School of Medicine, Sacramento, CA, ²Clinical Research, CPMC Research Institute, SF, CA, ³Int Medicine, UC Davis, School of Medicine, Sacramento, CA, ⁴Clinical Research, CPMC Research Institute, San Francisco, CA, ⁵Int Medicine, Portland, OR, ⁶Sacramento, CA
Background/Purpose: Normal mineral metabolism is critical for skeletal integrity. Uric acid (UA) is produced from purines by the enzyme xanthine oxidase, and elevated levels may…
Abstract Number: 822 • 2012 ACR/ARHP Annual Meeting
Greater Than Expected Increased Mortality Following Fragility Fractures in Women and Men with Rheumatoid Arthritis
Shreyasee Amin¹, Sherine E. Gabriel², Sara J. Achenbach³, Elizabeth J. Atkinson³ and L. Joseph Melton III⁴, ¹Rheumatology and Health Sciences Research, Mayo Clinic, Rochester, MN, ²Health Sciences Research & Div of Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Department of Hlth Sciences, Mayo Clinic, Rochester, MN
Background/Purpose: Women and men with RA are at an increased risk for fracture [fx] as well as greater overall mortality. It is recognized that in…
Abstract Number: 823 • 2012 ACR/ARHP Annual Meeting
Positive Effects of Tocilizumab On Bone Remodeling in Patients with Rheumatoid Arthritis
Karine Briot¹, Thierry Schaeverbeke², Fabien Etchepare³, Philippe Gaudin⁴, Aleth Perdriger⁵, Muriel Vray⁶, Stephanie Rouanet⁷, Ghislaine Steinberg⁸ and Christian Roux¹, ¹Cochin hospital, Paris Descartes University, Paris, France, ²Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ³G.H. Pitié-Salpêtrière, Paris, France, ⁴Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁵Rheumatology, Hôpital Sud, Rennes, France, ⁶Institut Pasteur, Paris, France, ⁷Medical Department, Roche, Boulogne-Billancourt, France, ⁸Medical Department, Roche, Neuilly sur Seine, France
Background/Purpose: The anti-IL6-R antibody tocilizumab (TCZ) is an effective treatment of rheumatoid arthritis (RA). Previous studies showed that TCZ has a positive effect on bone…
Abstract Number: 824 • 2012 ACR/ARHP Annual Meeting
Progressive Improvements in Cortical Mass and Thickness throughout the Hip Were Observed with Denosumab Treatment in the Freedom Trial
Ken Poole¹, Graham Treece¹, Andrew Gee¹, Jacques P. Brown², Michael McClung³, Andrea Wang⁴ and Cesar Libanati⁴, ¹University of Cambridge, Cambridge, United Kingdom, ²CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ³Oregon Osteoporosis Center, Portland, OR, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Denosumab (a RANK ligand antibody) reduces remodeling, increases bone mineral density, and reduces cortical porosity in postmenopausal women with osteoporosis. In FREEDOM, denosumab…
Abstract Number: 825 • 2012 ACR/ARHP Annual Meeting
Osteoporosis and Vertebral Fractures Are Important Determinants of Cardiovascular Disease in Rheumatoid Arthritis
Ausaf Mohammad¹, Derek Lohan², Diane Bergin², Sarah Mooney², John Newell³, Martin O'Donnell⁴, Robert J. Coughlan¹ and John J. Carey¹, ¹Rheumatology, Galway University Hospitals, Galway, Ireland, ²Radiology, Galway University Hospitals, Galway, Ireland, ³Clinical Research Facility, National University of Ireland, Galway, Ireland, ⁴Clinical Research Facility, Galway University Hospitals, Galway, Ireland
Background/Purpose: Cardiovascular disease(CVD) represents a major comorbidity and the leading cause of mortality for Rheumatoid arthritis(RA) patients. Unfortunately traditional risk factors for CVD underperform in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].